Soya, maize and sorghum ready-to-use therapeutic foods are more effective in correcting anaemia and iron deficiency than the standard ready-to-use therapeutic food: randomized controlled trial.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
24 Jun 2019
Historique:
received: 06 09 2018
accepted: 17 06 2019
entrez: 26 6 2019
pubmed: 27 6 2019
medline: 4 9 2019
Statut: epublish

Résumé

The prevalence of anaemia and iron deficiency (ID) among children with severe acute malnutrition (SAM) and their correction during nutritional rehabilitation are not well documented. This study assessed anaemia and ID prevalence and their predictors at start of SAM treatment, and the efficacy of their treatment and effect on gut health of two novel Ready-To-Use Therapeutic foods (RUTF) prepared from soybean, maize and sorghum (SMS) with (MSMS-RUTF) or without added milk (FSMS-RUTF) compared to those of the standard formulation prepared from peanut and milk (PM-RUTF). This was a 3-arms parallel groups, simple randomised, controlled non-inferiority trial in 6-59 months old Central Malawian children with SAM. Anaemia was defined using altitude- and ethnicity-adjusted haemoglobin. Iron status was defined using soluble transferrin receptor (sTfR) and body iron stores (BIS). We used Pearson's chi-square test, t-test for paired or unpaired data, Kruskal-Wallis test for between-arm differences as appropriate and logistic regression to identify independent predictors of anaemia or iron deficiency anaemia (IDA). The sample size was 389. At admission, the prevalence [%(95%CI)] of anaemia was 48.9(41.4-56.5)% while that of ID and IDA were 55.7(48.6-62.5)% and 34.3(28.2-41.0)% when using sTfR criterion and 29.1(24.4-34.4)% and 28.9(23.7-34.9)% when using BIS criterion, respectively. At discharge, nutrition rehabilitation with SMS-RUTF was associated with the lowest prevalence of anaemia [12.0(6.9-20.3)% for FSMS-RUTF, 18.2(11.9-26.8)% for MSMS-RUTF and 24.5(15.8-35.9)% for PM-RUTF; p = 0.023] and IDA [7.9(3.4-17.3)% for FSMS-RUTF, 10.9(4.8-22.6)% for MSMS-RUTF and 20.5(10.7-35.5)% for PM-RUTF; p = 0.028]. SMS-RUTF was also associated with the highest increase in BIS [Change in BIS (95%CI)] among the iron deplete at admission [6.2 (3.7; 8.6), 3.2 (0.8; 5.6), 2.2 (0.2; 4.3) for the same study arms; Anova p = 0.045]. Compared to P-RUTF, FSMS-RUTF had the highest adjusted recovery rate [OR (95%CI = 0.3 (0.2-0.5) with p < 0.001 for FSMS-RUTF and 0.6 (0.3-1.0) with p = 0.068 for MSMS-RUTF]. No effect of iron content on risk of iron overload or gut inflammation was observed. Anaemia and ID are common among children with SAM. FSMS-RUTF is more efficacious in treating anaemia and correcting BIS among this group than PM-RUTF. This study was registered on 15 April 2015 ( PACTR201505001101224 ).

Sections du résumé

BACKGROUND BACKGROUND
The prevalence of anaemia and iron deficiency (ID) among children with severe acute malnutrition (SAM) and their correction during nutritional rehabilitation are not well documented. This study assessed anaemia and ID prevalence and their predictors at start of SAM treatment, and the efficacy of their treatment and effect on gut health of two novel Ready-To-Use Therapeutic foods (RUTF) prepared from soybean, maize and sorghum (SMS) with (MSMS-RUTF) or without added milk (FSMS-RUTF) compared to those of the standard formulation prepared from peanut and milk (PM-RUTF).
METHODS METHODS
This was a 3-arms parallel groups, simple randomised, controlled non-inferiority trial in 6-59 months old Central Malawian children with SAM. Anaemia was defined using altitude- and ethnicity-adjusted haemoglobin. Iron status was defined using soluble transferrin receptor (sTfR) and body iron stores (BIS). We used Pearson's chi-square test, t-test for paired or unpaired data, Kruskal-Wallis test for between-arm differences as appropriate and logistic regression to identify independent predictors of anaemia or iron deficiency anaemia (IDA).
RESULTS RESULTS
The sample size was 389. At admission, the prevalence [%(95%CI)] of anaemia was 48.9(41.4-56.5)% while that of ID and IDA were 55.7(48.6-62.5)% and 34.3(28.2-41.0)% when using sTfR criterion and 29.1(24.4-34.4)% and 28.9(23.7-34.9)% when using BIS criterion, respectively. At discharge, nutrition rehabilitation with SMS-RUTF was associated with the lowest prevalence of anaemia [12.0(6.9-20.3)% for FSMS-RUTF, 18.2(11.9-26.8)% for MSMS-RUTF and 24.5(15.8-35.9)% for PM-RUTF; p = 0.023] and IDA [7.9(3.4-17.3)% for FSMS-RUTF, 10.9(4.8-22.6)% for MSMS-RUTF and 20.5(10.7-35.5)% for PM-RUTF; p = 0.028]. SMS-RUTF was also associated with the highest increase in BIS [Change in BIS (95%CI)] among the iron deplete at admission [6.2 (3.7; 8.6), 3.2 (0.8; 5.6), 2.2 (0.2; 4.3) for the same study arms; Anova p = 0.045]. Compared to P-RUTF, FSMS-RUTF had the highest adjusted recovery rate [OR (95%CI = 0.3 (0.2-0.5) with p < 0.001 for FSMS-RUTF and 0.6 (0.3-1.0) with p = 0.068 for MSMS-RUTF]. No effect of iron content on risk of iron overload or gut inflammation was observed.
CONCLUSIONS CONCLUSIONS
Anaemia and ID are common among children with SAM. FSMS-RUTF is more efficacious in treating anaemia and correcting BIS among this group than PM-RUTF.
TRIAL REGISTRATION BACKGROUND
This study was registered on 15 April 2015 ( PACTR201505001101224 ).

Identifiants

pubmed: 31234806
doi: 10.1186/s12889-019-7170-x
pii: 10.1186/s12889-019-7170-x
pmc: PMC6591918
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Equivalence Trial Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

806

Subventions

Organisme : Global Innovation Fund
ID : 01122015
Organisme : Ajinomoto Co. Inc
ID : 01122013
Organisme : The Japan International Cooperation Agency
ID : OS-JR-17047

Références

Lab Med. 2014 Spring;45(2):92-102
pubmed: 24868988
N Engl J Med. 2008 Feb 28;358(9):888-99
pubmed: 18305266
Am J Clin Nutr. 2010 May;91(5):1461S-1467S
pubmed: 20200263
Br J Nutr. 2001 May;85 Suppl 2:S175-9
pubmed: 11509107
Arch Latinoam Nutr. 1999 Sep;49(3 Suppl 2):11S-14S
pubmed: 10971831
Am J Clin Nutr. 1976 Aug;29(8):859-67
pubmed: 941868
J Pediatr Gastroenterol Nutr. 1985 Feb;4(1):97-102
pubmed: 3920380
Expert Rev Hematol. 2017 Nov;10(11):1023-1028
pubmed: 29023171
Science. 2013 Feb 1;339(6119):548-54
pubmed: 23363771
J Nutr. 2013 Mar;143(3):369-77
pubmed: 23343673
J Biopharm Stat. 2009 Nov;19(6):1055-73
pubmed: 20183464
Public Health Nutr. 2009 Apr;12(4):444-54
pubmed: 18498676
Food Nutr Bull. 2015 Mar;36(1 Suppl):S53-8
pubmed: 25902615
Clin Chim Acta. 2016 Apr 1;455:68-74
pubmed: 26828529
BMC Pediatr. 2017 Feb 2;17(1):46
pubmed: 28152989
Indian J Pediatr. 2015 Jun;82(6):511-4
pubmed: 25338494
Nutrients. 2016 Nov 02;8(11):
pubmed: 27827838
Food Nutr Bull. 2010 Jun;31(2 Suppl):S134-46
pubmed: 20715598
Lancet. 2006 Dec 2;368(9551):1992-2000
pubmed: 17141707
Am J Perinatol. 2015 Mar;32(4):337-42
pubmed: 25111039
Blood. 2003 May 1;101(9):3359-64
pubmed: 12521995
J Pediatr. 2009 Dec;155(6):823-828.e1
pubmed: 19628216
J Clin Pathol. 2009 Dec;62(12):1103-6
pubmed: 19946096
J Nutr. 2006 Sep;136(9):2435-8
pubmed: 16920866
J Nutr. 2009 Aug;139(8):1562-7
pubmed: 19535419
Lancet. 2007 Aug 11;370(9586):511-20
pubmed: 17693180
BMC Res Notes. 2017 Nov 7;10(1):570
pubmed: 29115985
J Nutr. 2017 Jan;147(1):125-132
pubmed: 27881597
Paediatr Perinat Epidemiol. 2003 Oct;17(4):384-90
pubmed: 14629321
Biol Trace Elem Res. 2008 Jul;124(1):1-11
pubmed: 18483793
Eur J Clin Nutr. 1999 Aug;53(8):669-73
pubmed: 10477255
Lancet. 2006 Jan 14;367(9505):133-43
pubmed: 16413877
Am J Clin Nutr. 2017 Dec;106(Suppl 6):1663S-1671S
pubmed: 29070549
Nature. 2014 Jun 19;510(7505):417-21
pubmed: 24896187
J Nutr. 2002 Jul;132(7):2117S-2122S
pubmed: 12097705
Nutrition. 2014 Apr;30(4):440-2
pubmed: 24332525
Am J Clin Nutr. 2017 Dec;106(Suppl 6):1688S-1693S
pubmed: 29070552
Korean J Anesthesiol. 2017 Aug;70(4):407-411
pubmed: 28794835
Am J Clin Nutr. 1978 Jan;31(1):46-56
pubmed: 413429
Blood Rev. 2017 Jul;31(4):225-233
pubmed: 28216263
Am J Public Health. 1989 Mar;79(3):340-9
pubmed: 2916724
Lancet. 2009 Jul 11;374(9684):136-44
pubmed: 19595348
Am J Trop Med Hyg. 2013 Apr;88(4):757-64
pubmed: 23382166
Lancet Glob Health. 2013 Jul;1(1):e16-25
pubmed: 25103581
Clin Nutr. 2010 Dec;29(6):773-8
pubmed: 20627488
Biomedicine. 1975 Jul;22(4):291-7
pubmed: 819052
Food Nutr Bull. 2006 Sep;27(3 Suppl):S49-82
pubmed: 17076213
Nutr Rev. 2017 Jan;75(1):49-60
pubmed: 27974599
Aliment Pharmacol Ther. 2004 Oct 1;20(7):813-9
pubmed: 15379842
Am J Clin Nutr. 2017 Dec;106(Suppl 6):1681S-1687S
pubmed: 29070544
Malar J. 2018 Dec 11;17(1):464
pubmed: 30537973
BMC Med. 2014 Aug 14;12:133
pubmed: 25189855
Am J Clin Nutr. 2004 Oct;80(4):973-81
pubmed: 15447908
J Nutr. 2004 Nov;134(11):3127-32
pubmed: 15514286
J Nutr. 2007 Apr;137(4):1023-30
pubmed: 17374671
Arch Pediatr. 2015 Nov;22(11):1188-97
pubmed: 26433575
Hemoglobin. 2015;39(2):141-3
pubmed: 25806419
J Nutr. 2017 Sep;147(9):1785-1794
pubmed: 28768839
J Nutr. 2014 Nov;144(11):1703-9
pubmed: 25332469
Am J Clin Nutr. 2017 Oct;106(4):1100-1112
pubmed: 28814393
Ann Clin Biochem. 2012 Jan;49(Pt 1):55-8
pubmed: 21930735
J Nutr. 2013 Aug;143(8):1233-9
pubmed: 23761652
J Res Med Sci. 2014 Feb;19(2):164-74
pubmed: 24778671
Am J Clin Nutr. 1989 Mar;49(3):546-52
pubmed: 2923087
Nutr Res Rev. 1989 Jan;2(1):29-49
pubmed: 19094345
J Nutr. 2015 May;145(5):1137S-1143S
pubmed: 25833890
Blood. 2014 Jan 30;123(5):615-24
pubmed: 24297872
Am J Clin Nutr. 2003 Aug;78(2):302-7
pubmed: 12885713
Gut. 2015 May;64(5):731-42
pubmed: 25143342
Cochrane Database Syst Rev. 2016 Feb 27;2:CD006589
pubmed: 26921618
Lancet. 1999 May 22;353(9166):1767-8
pubmed: 10347999
Adv Nutr. 2017 Jan 17;8(1):126-136
pubmed: 28096133
N Engl J Med. 2015 May 7;372(19):1832-43
pubmed: 25946282
Trop Med Int Health. 2008 Oct;13(10):1267-71
pubmed: 18721184
Adv Nutr. 2016 Mar 15;7(2):349-56
pubmed: 26980818
Br J Nutr. 2007 Feb;97(2):307-14
pubmed: 17298699
Pediatr Hematol Oncol. 2014 May;31(4):349-58
pubmed: 23987917
Curr Opin Clin Nutr Metab Care. 2016 Nov;19(6):458-463
pubmed: 27583708
Am J Clin Nutr. 2010 Sep;92(3):546-55
pubmed: 20610634
Sante. 2000 Mar-Apr;10(2):97-102
pubmed: 10960806
Anemia. 2014;2014:576738
pubmed: 24818016
Ann Clin Biochem. 2004 May;41(Pt 3):230-2
pubmed: 15117438
Nutrients. 2017 Jul 14;9(7):
pubmed: 28708072
Nutrients. 2017 Jul 19;9(7):
pubmed: 28753958
Nutrients. 2017 Jul 03;9(7):
pubmed: 28671630
Cent Afr J Med. 1988 Mar;34(3):39-43
pubmed: 3149208
Br J Nutr. 2014 Aug 28;112(4):547-56
pubmed: 24916165
PLoS One. 2014 Feb 19;9(2):e87796
pubmed: 24586292
Am J Clin Nutr. 2016 Apr;103(4):1145-61
pubmed: 26984485

Auteurs

Peter Akomo (P)

Valid Nutrition, Cuibín Farm, Derry Duff, Bantry, Co., Cork, Republic of Ireland. peterakomo@validnutrition.org.

Paluku Bahwere (P)

Valid International, 35 Leopold Street, Oxford, OX4 1TW, UK.
Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de santé publique, Université Libre de Bruxelles, Bruxelles, Belgium.

Hitoshi Murakami (H)

Nutrition Improvement Department, Ajinomoto Co., Inc., Tokyo, Japan.

Chrissy Banda (C)

Valid International, 35 Leopold Street, Oxford, OX4 1TW, UK.

Elizabeth Maganga (E)

MOH-Malawi, Lilongwe, Malawi.

Sylvester Kathumba (S)

MOH-Malawi, Lilongwe, Malawi.

Kate Sadler (K)

Valid International, 35 Leopold Street, Oxford, OX4 1TW, UK.

Steve Collins (S)

Valid Nutrition, Cuibín Farm, Derry Duff, Bantry, Co., Cork, Republic of Ireland.
Valid International, 35 Leopold Street, Oxford, OX4 1TW, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH